FOXO3 and sarcopenia: Even though in the context of sarcopenia, FoxO3 only recruits the newly imported β-catenin in nuclei and does not affect β-catenin binding on canonical targets, high dosage of FoxO3 may further compete β-catenin away from canonical Wnt targets and inhibit Wnt signaling.